19 May 2013
Keywords: Eli Lilly, Transition Therapeutics, Licensing, Diabetes compounds
Article | 04 March 2010
Canada’s Transition Therapeutics says that it has acquired the rights to a series of preclinical compounds from US drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 March 2010
17 May 2013
© 2013 thepharmaletter.com